ArticleInternational urology and nephrology2013
Role of asymmetric dimethylarginine in the progression of carotid atherosclerosis in renal transplant patients.
Article in International urology and nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation.Clinical journal of the American Society of Nephrology : CJASN · 2015Article
- Circulating CD133+ CD34+ progenitor cells and plasma stromal-derived factor-1alpha: predictive role in ischemic stroke patients.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2015Article
- Asymmetric dimethylarginine attenuates serum starvation-induced apoptosis via suppression of the Fas (APO-1/CD95)/JNK (SAPK) pathway.Cell death & disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDS/
aimsAtherosclerotic cardiovascular diseases are among the major causes of mortality in renal transplant (RT) patients. Oxidative stress plays an important role in the pathogenesis of atherosclerosis. In this study, we investigated the role of asymmetric dimethylarginine (ADMA) along with oxidized LDL (oxLDL) and antioxidized LDL (anti-oxLDL) on the extent and progression of atherosclerosis measured by carotid artery intima-media thickness (CA-IMT) in RT patients.
methodsOne hundred and eighty renal transplant patients were studied. Baseline and 25th month CA-IMT were determined by B-mode Doppler ultrasonography. ADMA, oxLDL and anti-oxLDL were measured by commercially available ELISA.
resultsThe mean age of the patients was 41 ± 9 years. The mean CA-IMT at baseline was 0.61 ± 0.15 mm. Age, cardiovascular disease and diabetes history, proteinuria and triglyceride levels were positively correlated, whereas HDL and albumin were negatively correlated with baseline CA-IMT. Ninety-two patients underwent a second CA-IMT measurement at a mean follow-up of 25th months. The mean second CA-IMT was 0.68 ± 0.18 mm. Serum ADMA levels, HCV positivity and albumin levels were predictors for CA-IMT progression in the multivariate analysis that included age, HCV positivity ADMA, albumin, glucose and proteinuria. OxLDL and anti-oxLDL were not associated with both CA-IMT presence and progression.
conclusionSerum ADMA levels predict progression of atherosclerosis in RT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.